Preservative-Free Prostaglandin Ophthalmic Solution Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Prostaglandin-based ophthalmic solutions face challenges with chemical stability over time and compatibility with low-density polyethylene packaging, particularly due to the toxicity of antimicrobial preservatives like benzalkonium chloride, which are also required for microbial protection.
Innovation Solution
The use of Solutol HS15 as a solubilizing agent instead of polysorbate 80 provides stability to prostaglandin solutions at ambient temperature and with LDPE packaging, eliminating the need for antimicrobial preservatives while maintaining solubility and chemical stability for 18 to 24 months.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antimicrobial preservatives like benzalkonium chloride are used in prostaglandin-based ophthalmic solutions, then microbial protection is achieved, but toxicity and tolerance problems arise with long-term use
Solution Approach 1:
The patent removes the harmful preservative component (benzalkonium chloride) from the ophthalmic solution formulation while maintaining the therapeutic efficacy of prostaglandins through alternative preservative-free stabilization methods
Solution Approach 2:
The patent introduces alternative stabilizing agents and packaging modifications that act as intermediaries to protect the solution without requiring toxic preservatives, enabling preservative-free formulation that maintains stability and microbial protection through physical barriers
2Reliability
If prostaglandins are incorporated into ophthalmic solutions, then glaucoma treatment is achieved, but chemical stability over time and compatibility with LDPE packaging are compromised
Solution Approach 1:
The patent modifies formulation parameters by changing the solubilizing agent from polysorbate 80 to Solutol HS15, which fundamentally alters the chemical stability profile and enables compatibility with LDPE packaging at ambient temperature
Solution Approach 2:
The patent creates a composite formulation system combining prostaglandins with Solutol HS15 and compatible excipients, forming a stable multi-component system that maintains chemical integrity over 18-24 months and interacts favorably with LDPE packaging materials
3Stability of the object's composition
If polysorbate 80 is used as solubilizing agent, then some stability is achieved, but compatibility with LDPE packaging and long-term stability at ambient temperature are insufficient
Solution Approach 1:
The patent changes the solubilizing agent parameter from polysorbate 80 to Solutol HS15, which fundamentally improves both solution stability and long-term storage stability at ambient temperature, extending the shelf life to 18-24 months without requiring cold storage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Solutol HS15 ensures the stability and solubility of prostaglandins in ophthalmic solutions, allowing for preservative-free formulations that are compatible with LDPE packaging, enhancing safety and efficacy for glaucoma treatment by reducing toxicity risks associated with antimicrobial preservatives.
Implementation Method 1
incorporating them into an ophthalmic solution requires a preliminary solubilization step
Implementation Method 2
the requirement to provide an ophthalmic solution which is chemically stable over time, in practice for a period of between 18 and 24 months
Implementation Method 3
it has to be stable relative to the packaging in which it is stored, in particular relative to packaging in low-density polyethylene (LDPE) material
Data Source
AI summary
The present invention provides an ophthalmic solution without an antimicrobial preservative. The solution includes as an active substance at least one prostaglandin and as a solubilizing agent, a surfactant, where the solubilizing agent is polyoxyl-15-hydroxystearate.